University Hospital Mannheim

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro

Retrieved on: 
Wednesday, February 21, 2024
Nobel Prize, Bial, University of Glasgow, Messenger, Synapse, Teaching hospital, Glioblastoma, Neuron, Neoplasm, Thought, University Hospital Heidelberg, University of Bergen, Vaccine, University, Haukeland University Hospital, COVID-19, Memory, Glioma, Jury, Heidelberg University, University Hospital Mannheim, Brain, Epilepsy, Tissue, Research, German Cancer Research Center, Medical imaging

This is possible by formation of synapses between neurons and cancer cells.

Key Points: 
  • This is possible by formation of synapses between neurons and cancer cells.
  • This paper shows that cancer cells cannot merely proliferate - they have to hijack healthy biological processes and integrate themselves into the normal function of tissues.
  • "Nowhere is this more blatant - and surprising - than in the brain tumours studied in this paper", says Ralph Adolphs.
  • The award-winning research also provides a new explanation for why epilepsy and tumour progression are often observed together: epilepsy may be a cause, rather than a consequence of the tumour progression.

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

Retrieved on: 
Tuesday, February 6, 2024
TRON, Antigen, DKFZ, Peptide, Research, Heart, Teaching hospital, Map, Patient, H3, Epitope, Ligand, Vaccination, HLA, Doctor of Philosophy, University, Ed Green, Health, Cancer, University Hospital Mannheim, Glioma, Vaccine

The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.

Key Points: 
  • The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.
  • Dr. John M. Lindner and his research team at the BioMed X Institute in Heidelberg designed the T-FINDER platform to solve this problem.
  • This work provides key insights into the mechanism of anti-tumor T cell responses in these patients and will support ongoing vaccination studies.
  • "Previously, we have been limited in the tools we could use to study class II-presented epitopes such as mutant H3.

Brain Aneurysm Foundation Expands its Medical Advisory Board with Leading Experts from Brazil and Germany

Retrieved on: 
Wednesday, January 10, 2024
Rupture, Research, Interventional neuroradiology, Knowledge, Harvard Medical School, Intervention, Society, Risk, University Hospital Mannheim, Guideline, Professor, Paulo, Policy, Stroke, Global Reach, Disease, Congress, Skull, Radiology, Brain, Education, Physician, Aneurysm, CNS, Health, World government, Woman, Organization, Hospital, Death, Patient, Subarachnoid hemorrhage, ESO, Blood, Nursing

HANOVER, Mass., Jan. 10, 2024  /PRNewswire/ -- The Brain Aneurysm Foundation (BAF), the leading advocacy organization supporting education, research, and policy to transform the treatment of brain aneurysms, today announced it has appointed to its Medical Advisory Board Carlos Baccin, M.D., an interventional neuroradiologist and Director of the Institute of Radiology and NeuroIntervention in São Paulo, Brazil, and Nima Etminan, Professor and Chairman of the Department of Neurosurgery at University Hospital Mannheim, in Germany.

Key Points: 
  • Worldwide, there are close to 500,000 deaths each year from brain aneurysms, half of which occur in people under the age of 50.
  • Dr. Etminan has published over 120 papers in leading medical journals, primarily in the field of unruptured intracranial aneurysms or aneurysmal subarachnoid hemorrhage.
  • A brain aneurysm is a weak, bulging area in an artery in the brain that, in some instances, can rupture.
  • Women over the age of 55 have a higher risk of brain aneurysm rupture than men and are generally at greater risk.

DGAP-News: SphingoTec appoints Jörg Menten as CEO to accelerate commercialization and global growth

Retrieved on: 
Thursday, June 30, 2022
Nexus, Incident management team, Diagnosis, Acquisition, Patient, Sepsis, CEO, N-terminal prohormone of brain natriuretic peptide, Precision medicine, Research, Adoption, PCT, Interventional radiology, Roche Diagnostics, Biomarker, DPP3, Growth, Liver cancer, Boston Scientific, CSO, CCO, CFO, MBA, Hennigsdorf, IVD, TSH, University, NYSE, University Hospital Mannheim, Point of care, Advisory board, CA, Advisory, The Advisory Board Company, Leadership, POC, IPO, Vanguard, Senior management, Management, Medical device, Critical care, Troponin

SphingoTec appoints Jrg Menten as Chief Executive Officer (CEO) as from July 1, 2022 to drive the commercialization and scale its diagnostic business.

Key Points: 
  • SphingoTec appoints Jrg Menten as Chief Executive Officer (CEO) as from July 1, 2022 to drive the commercialization and scale its diagnostic business.
  • Hennigsdorf/Berlin, Germany, June 30, 2021 Diagnostics company SphingoTec GmbH (SphingoTec) today announced that Jrg Menten was appointed CEO of SphingoTec effective of July 1, 2022.
  • Jrg Menten is a highly skilled senior executive with a long-standing track record of leadership positions in the global healthcare industry.
  • On behalf of the Advisory Board I welcome Jrg Menten in his new capacity as CEO of SphingoTec.

DGAP-News: SphingoTec Appoints Jörg Menten to Leadership Team as Chief Commercial Officer to Drive New Business Growth

Retrieved on: 
Monday, November 29, 2021
Nexus, VAC, Adoption, CEO, Biomarker, Acquisition, Hospital, NYSE, Roche Diagnostics, Diagnosis, POC, MBA, IPO, IVD, University, Boston Scientific, N-terminal prohormone of brain natriuretic peptide, Laboratory, Dipeptidyl peptidase-4 inhibitor, Heart, Myocardial infarction, DPP3, Critical care, Liver cancer, CFO, Wound healing, Vanguard, CA, Interventional radiology, University Hospital Mannheim, Embolism, Hennigsdorf, Sepsis, TSH, PCT, Management, Medical imaging, Pharmaceutical industry

SphingoTec expands leadership team to facilitate scaling of its fast-growing diagnostics business.

Key Points: 
  • SphingoTec expands leadership team to facilitate scaling of its fast-growing diagnostics business.
  • Jrg Menten will lead the company's commercial efforts and drive expansion into global markets.
  • Hennigsdorf/Berlin, Germany, November 29, 2021 - Diagnostics company SphingoTec GmbH ("SphingoTec") today announced the appointment of Jrg Menten as its Chief Commercial Officer.
  • "We are committed to bringing personalized medicine to critical care," said Dr. Andreas Bergmann, Chief Executive Officer and founder of SphingoTec.